WALDENCAST ACQUISITION CORP
NASDAQ: WALD (Waldencast plc)
Last update: 2 days ago, 12:35AM1.64
-0.01 (-0.61%)
| Previous Close | 1.65 |
| Open | 1.65 |
| Volume | 52,334 |
| Avg. Volume (3M) | 99,144 |
| Market Cap | 203,288,160 |
| Price / Sales | 0.700 |
| Price / Book | 0.420 |
| 52 Weeks Range | |
| Earnings Date | 17 Mar 2026 |
| Profit Margin | -15.50% |
| Operating Margin (TTM) | -18.31% |
| Diluted EPS (TTM) | -0.390 |
| Quarterly Revenue Growth (YOY) | 30.80% |
| Total Debt/Equity (MRQ) | 24.95% |
| Current Ratio (MRQ) | 1.35 |
| Operating Cash Flow (TTM) | -8.82 M |
| Levered Free Cash Flow (TTM) | 8.34 M |
| Return on Assets (TTM) | -3.32% |
| Return on Equity (TTM) | -6.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Household & Personal Products (US) | Bearish | Bearish |
| Household & Personal Products (Global) | Bearish | Bearish | |
| Stock | Waldencast plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.38 |
|
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region. |
|
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Investment Style | Small Value |
| % Held by Insiders | 56.95% |
| % Held by Institutions | 25.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Zeno Equity Partners Llp | 30 Sep 2025 | 12,252,580 |
| Milestones Administradora De Recursos Ltda. | 30 Sep 2025 | 2,425,677 |
| Mcadam, Llc | 30 Sep 2025 | 63,014 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (Canaccord Genuity, 143.90%) | Buy |
| Median | 3.00 (82.93%) | |
| Low | 2.00 (Jefferies, 21.95%) | Buy |
| Average | 3.00 (82.93%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 2.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 14 Jan 2026 | 2.00 (21.95%) | Buy | 1.63 |
| Canaccord Genuity | 25 Nov 2025 | 4.00 (143.90%) | Buy | 2.56 |
| Telsey Advisory Group | 25 Nov 2025 | 3.00 (82.93%) | Hold | 2.56 |
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update |
| 16 Nov 2025 | Announcement | Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting |
| 14 Nov 2025 | Announcement | Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities |
| 12 Nov 2025 | Announcement | Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |